Shifting Paradigm in Treating Brain Tumors
Who We Are
We’re a young and dynamic group of entrepreneurs, scientists, and engineers equipped with groundbreaking technologies in the neuro-oncology space determined to provide better treatment options for patients involved with some of the most deadly cancers. At Exvade Bioscience, we believe that the right combination of scientific understanding of the disease, the stakeholders involved, and technological edge can lead us towards an impactful innovation.
Malignant Brain Tumors
Primary brain tumors are unique in that they rarely metastasize outside the brain. Nevertheless, brain tumors are characterized by high morbidity and mortality partly due to their localization and often locally invasive growth. Gliomas, tumors arising from glial cells, account for almost 30% of all primary brain tumors, and 80% of all malignant ones, and are responsible for the majority of deaths from primary brain tumors.
WHO grade IV gliomas–glioblastoma multiforme (GBM), are the most malignant and frequently occurring gliomas. For patients with newly diagnosed GBM, the therapeutic regimen is maximally safe and feasible resection of the tumor mass, followed by concomitant and adjuvant temozolomide (TMZ) plus radiotherapy
followed by TMZ alone. Despite these measures, survival rates of GBM patients have remained dismal, with little improvement over the last 50 years.
‘Exvading’ the Tumor
Exploiting the invasive nature of GBMs to prevent further invasion and spread of the cancer cells
"Big results require big ambitions"
Get in Touch
Exvade Bioscience Inc
380 Northyards Blvd. Suite A
Atlanta, GA 30313